Get it on Google Play

IMUNON's Phase 2 ovarian cancer study cleared to continue after safety review

September 22, 2026 8:05 AM EDT Send to a Friend
IMUNON, Inc. (Nasdaq: IMNN) announced that an Independent Data Monitoring Committee (IDMC) has reviewed all safety data from the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login